Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.
The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| IPO Date | Apr 1, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Patrick J. Holt |
Contact Details
Address: Spaces South Docklands, Block C, 77 Sir John Rogerson's Quay Dublin 2, L2 D02 VK60 Ireland | |
| Phone | 353 1 6699 020 |
| Website | amarincorp.com |
Stock Details
| Ticker Symbol | AMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000897448 |
| CUSIP Number | 023111206 |
| ISIN Number | US0231112063 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Patrick J. Holt | President, Chief Executive Officer and Director |
| Thomas Charles Reilly | Executive Vice President, Chief Financial Officer and Global Head of Human Resources |
| Dr. Steven B. Ketchum Ph.D. | Executive Vice President, President of Research and Development and Chief Scientific Officer |
| Jonathan N. Provoost | Executive Vice President, Chief Legal and Compliance Officer and Secretary |
| Aaron D. Berg | Executive Vice President and President of U.S. |
| Jordan Zwick | Senior Vice President of Corporate Business Development and Investor Relations |
| Laurent Abuaf | President of Europe and Senior Vice President |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs |
| Dr. David Keenan Ph.D. | Executive Vice President of Technical Operations and President of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 4, 2024 | ARS | Filing |
| Mar 4, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 10, 2024 | 8-K | Current Report |
| Dec 12, 2023 | 144 | Filing |